FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.
FDA is allowing ZYN nicotine pouches, a tobaccoless product that has soared in popularity since in recent years, to make the claim that its products are safer than cigarettes.
